The popularity of Sildenafil initially drove a boom for the drug industry, however recent changes present a murky scenario for shareholders. Generic alternatives are eating into profits, and ongoing patent challenges https://karimlebo365173.post-blogs.com/62033415/the-blue-pill-and-pharma-a-risky-investment